Prophase Labs, INC

ProPhase Labs, Inc. has entered into a senior secured convertible loan agreement for $2,085,000, receiving net proceeds of $1,020,000 after fees and reserves.

ProPhase Labs initiates a strategic process for its BE-Smart esophageal cancer test and provides a positive update on its Crown Medical Collections initiative, aiming for significant liquidity.

ProPhase Labs invites investors to a webinar featuring CEO Ted Karkus to discuss its high-growth healthcare portfolio and strategic initiatives.

ProPhase Labs provides an operational update on its Crown Medical Collections initiative, engaging over 250 payors with 50 matters in advanced settlement for legacy COVID-19 testing receivables.

ProPhase Labs' common stock has been approved for uplisting from the Pink Sheets to the OTC market, signaling a move towards greater transparency and investor access.

ProPhase Labs, Inc. has entered into a Stock Purchase Agreement with Generating Alpha Ltd. for an equity line facility providing up to $10 million in equity capital.

ProPhase Labs files an amended 10-Q report for Q1 2026, restating financial statements due to identified errors in revenue, cost of goods sold, and deferred revenue.

ProPhase Labs amends its Q1 2026 10-Q filing due to auditor review completion, reporting a net loss and significant liquidity challenges.

ProPhase Labs reports a significant decrease in revenue for Q1 2026 compared to the prior year, primarily due to a decline in consumer product sales, while continuing to address substantial going concern issues.

ProPhase Labs reported a net loss of $6.8 million for Q3 2025, driven by declining consumer product revenue and increased interest expense, while advancing its BE-Smart diagnostic test and facing a Nasdaq delisting warning.

ProPhase Labs reported a narrower net loss and significantly improved gross margins in Q2 2025, driven by strategic divestitures and a focus on higher-margin consumer products, despite a decline in overall revenue.

ProPhase Labs reports a net income of $3.966 million for Q1 2025, driven by the sale of Pharmaloz Manufacturing, despite a decrease in overall revenue compared to Q1 2024.

ProPhase Labs reports a net loss of $14.7 million for 2025, following the Chapter 11 bankruptcy filing of its diagnostic subsidiaries and a strategic shift toward genomics and biotechnology.

ProPhase Labs files an amendment to its 2024 Annual Report on Form 10-K to include previously omitted information regarding directors, executive officers, corporate governance, executive compensation, security ownership, related transactions, principal accountant fees, and a subsequent event relating to executive salary deferrals.

ProPhase Labs reports a significant revenue decrease in 2024 due to reduced diagnostic services, while focusing on genomics and biopharmaceutical growth.

ProPhase Labs has filed an amendment to its annual report to include previously omitted information regarding directors, executive compensation, and corporate governance.

ProPhase Labs has amended and restated its bylaws, outlining procedures for stockholder meetings, director nominations, and other corporate governance matters.

ProPhase Labs' CEO and Chairman, Ted Karkus, was issued 500,000 warrants to purchase common stock at $0.60 per share following shareholder approval of an increase in authorized shares.

ProPhase Labs' Chief Operating Officer, Stuart Hollenshead, was granted stock options as an inducement award.

Director Warren Hirsch acquired options to purchase 100,000 shares of ProPhase Labs common stock on February 14, 2025.

Director Louis Gleckel acquired options to purchase 100,000 shares of ProPhase Labs stock on February 14, 2025.

Ted Karkus, CEO & Chairman of ProPhase Labs, files an amended Form 4 to correct the reporting of a 400,000 share option grant.

Director Jed Latkin acquired 500,000 stock options in ProPhase Labs, Inc. on January 1, 2024.

ProPhase Labs seeks stockholder approval for a comprehensive digital asset and crypto treasury management strategy, alongside measures to maintain its Nasdaq listing, including a potential stock split.

ProPhase Labs has postponed its Special Meeting of Shareholders to September 9, 2025, to allow for proper dissemination of definitive proxy materials, which include proposals for a crypto treasury strategy and increased authorized shares.

ProPhase Labs, Inc. calls a Special Meeting to vote on proposals to significantly increase authorized shares, approve a large private placement, and enable a new crypto treasury strategy.

ProPhase Labs, Inc. is preparing for its 2025 Annual Meeting of Stockholders, addressing significant financial losses, a sharp decline in Total Shareholder Return, and a Nasdaq compliance issue related to its Audit Committee, while also disclosing executive compensation and related party transactions.

ProPhase Labs announces its 2024 Annual Meeting of Stockholders to be held on June 20, 2024, with key proposals including the election of directors and ratification of the independent auditor.

ProPhase Labs files S-1 to register up to 226 million common shares for resale by selling stockholders, following a private placement and amidst significant business restructuring and Nasdaq compliance challenges.